Microbot Medical to Fully Launch LIBERTY System in 2026
Microbot Medical is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several pivotal achievements such as obtaining FDA 510(k) clearance for LIBERTY, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The Company initiated its limited market release, quickly achieving its first customer to adopt LIBERTY for patient care. The Company is positioning itself to leverage this momentum and commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually. This progress enables the Company to pursue and strive for the 2026 anticipated milestones listed. Anticipated 2026 Operational and Commercial Milestones Commence the Full Market Release of the LIBERTY System in Q2 2026, in conjunction with the Society of Interventional Radiology conference. Grow customer base by attracting early adopters and securing new hospitals with medium-to-high volume target procedures. Validate the LIBERTY System's significant market opportunity, with the expansion of the types of procedures that are being performed as well as the end user call point to include interventional radiologists, vascular surgeons, and interventional cardiologists. Establish commercial and operational infrastructure to support expansion into markets outside the USA, either under FDA Clearance or other regional and local regulatory approvals. Enhance the Company's core capabilities by filling cross-functional roles with the right talent to support execution and future growth. Maintain a strong presence at key medical societies and conferences, including the Society of Interventional Oncology and International Symposium on Endovascular Therapy in February, Society of Interventional Radiology in April, Global Embolization Symposium and Technologies in May and Cardiovascular and Interventional Radiological Society of Europe in September. Continue to establish pipelines to allow future growth to other interventional spaces and increase the utilization opportunity within the peripheral space. Continue collaborations with leading institutions in the areas of teleintervention and autonomous robotics and explore additional opportunities to leverage the innovative LIBERTY technology. Expand and protect the Company's global IP portfolio, which creates barriers to entry, and allows the Company to monetize its innovative technology. Leverage the strong balance sheet to fully execute its near and medium-term commercial strategy in the U.S. and globally, and to support its product development pipeline.
Get Free Real-Time Notifications for Any Stock
Analyst Views on MBOT
About MBOT
About the author

Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.

HC Wainwright & Co. Affirms Buy Rating for Microbot Medical, Keeps $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and resources.
Market Winning Tools: The platform is designed to provide traders with the tools they need to succeed in the markets every day.









